Larimar Therapeutics PEG Ratio

The latest PEG ratio for LRMR is -160.43. That is below the Healthcare sector average of 11.64. Investors often review this figure alongside Larimar Therapeutics's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, LRMR currently prints -160.43 for PEG ratio, while the sector average sits near 11.64. That is roughly 1478.2% below the sector mean. Large gaps often invite a closer look at Larimar Therapeutics's growth, margins, and balance sheet.

A PEG ratio of -160.43 for Larimar Therapeutics is not 'good' or 'bad' on its own. Compare it with the peer average (11.64) and with LRMR's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting LRMR's PEG ratio (-160.43), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Larimar Therapeutics's PEG ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.